BURLINGTON, Mass.--(BUSINESS WIRE)--
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite a decline in sales owing to the generic entry of most triptans, the launch of emerging acute treatments and the uptake of Allergan’s Botox for prevention of chronic migraine will drive the market for migraine therapies to increase from $3.3 billion in 2011 to $5.8 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The Pharmacor advisory service entitled Migraine finds that increasing physician understanding of the indication and the launches of many generic triptans over the next several years will steadily increase diagnosis and drug-treatment rates, leading to sustained annual growth through 2021. Although migraine is a highly prevalent condition—affecting more than 75 million people across the seven major markets—a lack of importance attributed to headache and the availability of OTC analgesics lead to low diagnosis rates, and the high cost of some prescription therapies leads to low drug-treatment rates.
“Interviewed experts agree that the highest unmet need in migraine treatment is for prophylactic therapies with improved efficacy and/or tolerability,” said Decision Resources Analyst Anne-Elise Tobin, Ph.D. “However, few prophylactic therapies are in development, and we do not forecast the launch of any emerging prophylactics through 2021.”
The findings also reveal that although many generic acute treatments are available and all triptans will be generically available in the U.S. and European markets by 2015, opportunity remains to address unmet needs in certain niche populations, namely in patients who do not respond satisfactorily to triptans or in whom triptans are contraindicated. In addition, opportunity will persist for novel acute migraine treatments that offer improved efficacy over the triptans.
Through 2021, two nontriptan acute therapies will launch for migraine—MAP Pharmaceuticals/Allergan’s orally inhaled dihydroergotamine (Levadex) and CoLucid’s lasmiditan, a novel 5-HT1F receptor agonist. Neither treatment offers efficacy superior to that of the triptans, but both offer alternatives for triptan nonresponders. In addition, lasmiditan may be a first-line option for patients with cardiovascular disease, in whom triptans are contraindicated.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Christopher Comfort, 781-993-2597